FY2025 EPS Estimates for Alumis Cut by Cantor Fitzgerald

Alumis Inc. (NASDAQ:ALMS) – Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Alumis in a research report issued on Thursday, March 20th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earnings of ($5.36) per share for the year, down from their prior forecast of ($4.13). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

A number of other research firms also recently weighed in on ALMS. HC Wainwright restated a “buy” rating and issued a $15.00 target price (down previously from $19.00) on shares of Alumis in a research report on Thursday. Oppenheimer initiated coverage on Alumis in a research report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Alumis currently has a consensus rating of “Buy” and an average target price of $26.00.

Alumis Stock Performance

NASDAQ:ALMS opened at $3.75 on Monday. The business has a 50 day moving average of $5.69 and a 200 day moving average of $8.54. Alumis has a 1-year low of $3.18 and a 1-year high of $13.53.

Hedge Funds Weigh In On Alumis

Several hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC purchased a new stake in Alumis in the third quarter worth $3,266,000. State Street Corp purchased a new stake in Alumis in the third quarter worth $866,000. Charles Schwab Investment Management Inc. purchased a new stake in Alumis in the third quarter worth $1,160,000. Stifel Financial Corp purchased a new stake in Alumis in the third quarter worth $931,000. Finally, Barclays PLC purchased a new stake in Alumis in the third quarter worth $197,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.